These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 9819201)
1. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Usher KC; Blaszczak LC; Weston GS; Shoichet BK; Remington SJ Biochemistry; 1998 Nov; 37(46):16082-92. PubMed ID: 9819201 [TBL] [Abstract][Full Text] [Related]
2. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. Weston GS; Blázquez J; Baquero F; Shoichet BK J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697 [TBL] [Abstract][Full Text] [Related]
3. Nanomolar inhibitors of AmpC beta-lactamase. Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668 [TBL] [Abstract][Full Text] [Related]
4. Thermodynamic cycle analysis and inhibitor design against beta-lactamase. Roth TA; Minasov G; Morandi S; Prati F; Shoichet BK Biochemistry; 2003 Dec; 42(49):14483-91. PubMed ID: 14661960 [TBL] [Abstract][Full Text] [Related]
5. Functional analyses of AmpC beta-lactamase through differential stability. Beadle BM; McGovern SL; Patera A; Shoichet BK Protein Sci; 1999 Sep; 8(9):1816-24. PubMed ID: 10493583 [TBL] [Abstract][Full Text] [Related]
6. Thermodynamic evaluation of a covalently bonded transition state analogue inhibitor: inhibition of beta-lactamases by phosphonates. Nagarajan R; Pratt RF Biochemistry; 2004 Aug; 43(30):9664-73. PubMed ID: 15274621 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Nukaga M; Abe T; Venkatesan AM; Mansour TS; Bonomo RA; Knox JR Biochemistry; 2003 Nov; 42(45):13152-9. PubMed ID: 14609325 [TBL] [Abstract][Full Text] [Related]
8. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant. Sun T; Bethel CR; Bonomo RA; Knox JR Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561 [TBL] [Abstract][Full Text] [Related]
9. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535 [TBL] [Abstract][Full Text] [Related]
10. Kinetics of turnover of cefotaxime by the Enterobacter cloacae P99 and GCl beta-lactamases: two free enzyme forms of the P99 beta-lactamase detected by a combination of pre- and post-steady state kinetics. Kumar S; Adediran SA; Nukaga M; Pratt RF Biochemistry; 2004 Mar; 43(9):2664-72. PubMed ID: 14992604 [TBL] [Abstract][Full Text] [Related]
11. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. Wang X; Minasov G; Shoichet BK Proteins; 2002 Apr; 47(1):86-96. PubMed ID: 11870868 [TBL] [Abstract][Full Text] [Related]
12. Crystal structure of an acylation transition-state analog of the TEM-1 beta-lactamase. Mechanistic implications for class A beta-lactamases. Maveyraud L; Pratt RF; Samama JP Biochemistry; 1998 Feb; 37(8):2622-8. PubMed ID: 9485412 [TBL] [Abstract][Full Text] [Related]
13. Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase. Buzzoni V; Blazquez J; Ferrari S; Calò S; Venturelli A; Costi MP Bioorg Med Chem Lett; 2004 Aug; 14(15):3979-83. PubMed ID: 15225711 [TBL] [Abstract][Full Text] [Related]
14. Structure of a phosphonate-inhibited beta-lactamase. An analog of the tetrahedral transition state/intermediate of beta-lactam hydrolysis. Chen CC; Rahil J; Pratt RF; Herzberg O J Mol Biol; 1993 Nov; 234(1):165-78. PubMed ID: 8230196 [TBL] [Abstract][Full Text] [Related]
15. Structural aspects for evolution of beta-lactamases from penicillin-binding proteins. Meroueh SO; Minasov G; Lee W; Shoichet BK; Mobashery S J Am Chem Soc; 2003 Aug; 125(32):9612-8. PubMed ID: 12904027 [TBL] [Abstract][Full Text] [Related]
16. Structure-based approach for binding site identification on AmpC beta-lactamase. Powers RA; Shoichet BK J Med Chem; 2002 Jul; 45(15):3222-34. PubMed ID: 12109906 [TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a complex between the Actinomadura R39 DD-peptidase and a peptidoglycan-mimetic boronate inhibitor: interpretation of a transition state analogue in terms of catalytic mechanism. Dzhekieva L; Rocaboy M; Kerff F; Charlier P; Sauvage E; Pratt RF Biochemistry; 2010 Aug; 49(30):6411-9. PubMed ID: 20608745 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates. Venkatesan AM; Gu Y; Dos Santos O; Abe T; Agarwal A; Yang Y; Petersen PJ; Weiss WJ; Mansour TS; Nukaga M; Hujer AM; Bonomo RA; Knox JR J Med Chem; 2004 Dec; 47(26):6556-68. PubMed ID: 15588091 [TBL] [Abstract][Full Text] [Related]
19. Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Ibuka AS; Ishii Y; Galleni M; Ishiguro M; Yamaguchi K; Frère JM; Matsuzawa H; Sakai H Biochemistry; 2003 Sep; 42(36):10634-43. PubMed ID: 12962487 [TBL] [Abstract][Full Text] [Related]
20. The crystal structure of phosphonate-inhibited D-Ala-D-Ala peptidase reveals an analogue of a tetrahedral transition state. Silvaggi NR; Anderson JW; Brinsmade SR; Pratt RF; Kelly JA Biochemistry; 2003 Feb; 42(5):1199-208. PubMed ID: 12564922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]